An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.

@article{Horgan2011AnEA,
  title={An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.},
  author={Anne M. Horgan and Penelope Ann Bradbury and Eitan Amir and Raymond Wai-Man Ng and J. Y. Douillard and Edward S. Kim and Frances A. Shepherd and Natasha B Leighl},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 8},
  pages={1805-11}
}
BACKGROUND The INTEREST (IRESSA NSCLC Trial Evaluating Response and Survival against Taxotere) trial compared gefitinib with docetaxel (Taxotere) in pretreated advanced non-small-cell lung cancer (NSCLC). Noninferiority for overall survival was concluded. Gefitinib had a better toxicity profile and greater improvements in quality of life (QoL). We undertook a cost-consequence analysis to estimate the direct medical costs of gefitinib compared with docetaxel. PATIENTS AND METHODS Summary data… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Cost-utility of gefitinib versus docetaxel in a Mexican public institution

  • Anaya PLJ, AC Polanco
  • Poster PCN72l ISPOR, 14th Annual International…
  • 2009
1 Excerpt

Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC) in UK

  • GML Lewis, J Creeden
  • Value Health 2006;
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…